Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.52 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.38 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13408136 | 0.95 | MAPKAPK2 (0.57) | MAPKAPK2DYRK1BPRKD1PRKD2NPC1 | |
| Trifluoroacetic Acid SCHEMBL3616010 | 0.86 | MAPKAPK2 (0.41) | MAPKAPK2DYRK1BPRKD1CDC7PIM1 | |
| Trifluoroacetic Acid SCHEMBL3620664 | 0.85 | CCNC (0.44) | MAPKAPK2CDC7PIM1CDK9TGFBR1 | |
| SCHEMBL13408133 | 0.83 | ULK1 (0.43) | MAPKAPK2DYRK1BPRKD1CDC7PIM1 | |
| SCHEMBL3616693 | 0.82 | MAPKAPK2 (0.62) | MAPKAPK2DYRK1BPRKD1PRKD2ADRB1 | |
| Trifluoroacetic Acid SCHEMBL3619263 | 0.82 | ALDH1A1 (0.44) | MAPKAPK2CDC7PIM1CDK9MAPK14 | |
| Trifluoroacetic Acid SCHEMBL3614592 | 0.81 | PIM1 (0.39) | MAPKAPK2CDC7PIM1CDK9IRAK4 | |
| Trifluoroacetic Acid SCHEMBL3610696 | 0.81 | IRAK4 (0.42) | PRKD1PRKD2CDC7PIM1CDK9 | |
| Trifluoroacetic Acid SCHEMBL3616616 | 0.81 | RET (0.40) | PRKD1PRKD2IRAK4 | |
| Trifluoroacetic Acid SCHEMBL3616676 | 0.80 | MAPKAPK2 (0.39) | MAPKAPK2DYRK1BPRKD1PRKD2CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | claimed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | claimed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | claimed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | SLCO1B3, SLCO1B1, SLC10A6 | MAPKAPK2 4395/4885DYRK1B 4170/4885PRKD1 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.